Lilian founded Stern IR to provide differentiated investor and communications consulting to the healthcare industry, with a particular focus on biotechnology, including specialty pharmaceuticals, innovative diagnostics and tools, and vaccines. She got the idea that taking a strategic approach to investor relations was the best path to value creation, by crafting the IR program around the company’s financial goals. Throughout Stern IR’s history Lilian has committed to the key value that we do worthwhile work: contributing to human health by facilitating capital into the industry.
She’s very proud of initiating and participating in some of the firm’s key accomplishments:
Working with the team to represent over 500 companies during Stern IR’s tenure
Rolling out and positioning many multibillion dollar M&A transactions
Maintaining relationships with key elite venture capital firms, including Atlas Ventures, Flagship Pioneering, Polaris Ventures, Third Rock Ventures Versant Ventures and many others
Providing value to the talented investment bankers, analysts and equity capital markets professionals to finance Stern IR clients
Achieving success attracting the industry’s premier institutional investors to become stakeholders in clients
Lilian holds an A.B. from Cornell University in molecular biology and biochemistry and where she was a College Scholar, as well as a J.D. from Harvard Law School.